WM
79
3
AXP
71
2
DRI
53
5
XRX
44
3
BMY
60
2
PM
62
-2
APD
59
2
DVN
21
3
NVDA
56
-4
HBI
59
4
HP
48
3
UNP
52
7
TJX
64
2
BBY
46
10
STI
14
-17
BWA
48
2
KLAC
47
4
EFX
38
2
FLR
58
3
GT
62
6
WM
79
3
AXP
71
2
DRI
53
5
XRX
44
3
BMY
60
2
PM
62
-2
APD
59
2
DVN
21
3
NVDA
56
-4
HBI
59
4
HP
48
3
UNP
52
7
TJX
64
2
BBY
46
10
STI
14
-17
BWA
48
2
KLAC
47
4
EFX
38
2
FLR
58
3
GT
62
6
Financhill
Back

Halozyme Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
51

HALO
Halozyme Therapeutics

Last Price:
49.01
Seasonality Move:
17.34%

7 Day Trial

ALL ACCESS PASS

$ 7

Trade on Tuesday. Profit on Friday. Rinse & Repeat

Get the full details now.

Halozyme Therapeutics Price Quote

$49.01
+0.01 (+7.24%)
(Updated: November 23, 2024 at 5:38 AM ET)

Halozyme Therapeutics Key Stats

Buy
51
Halozyme Therapeutics (HALO) is a Buy
Day range:
$46.21 - $49.57
52-week range:
$33.15 - $65.53
Dividend yield:
0%
P/E ratio:
23.33
P/S ratio:
6.72
P/B ratio:
13.77%
Volume:
4.5M
Avg. volume:
1.9M
1-year change:
22.16%
Market cap:
$6.2B
Revenue:
$829.3M
EPS:
$3.02

How Much Does Halozyme Therapeutics Make?

Is Halozyme Therapeutics Growing As A Company?

  • What Is Halozyme Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.34%
  • What Is Halozyme Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0.72%

Halozyme Therapeutics Stock Price Performance

What Is Halozyme Therapeutics 52-Week High & Low?

Halozyme Therapeutics Price To Free Cash Flow

Is It Risky To Buy Halozyme Therapeutics?

Is Halozyme Therapeutics Cash Flow Positive?

  • What Is HALO Cash Flow From Operations?
    Cash flow from operations (TTM) is $403M
  • What Is Halozyme Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$222.4M
  • What Is Halozyme Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$300.5M

Halozyme Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    HALO return on invested capital is 22.41%
  • What Is Halozyme Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 20.54%
  • What Is HALO Return On Equity?
    ROE is a measure of profitability and is 156.62%

Halozyme Therapeutics Earnings Date & Stock Price

Halozyme Therapeutics Competitors

Halozyme Therapeutics Dividend Yield

Halozyme Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 72.13% 27.05%
Revenue: 34.28% 15.04%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 62.44
Upside from Last Price: 27.44%

Major Shareholders

  • How many HALO shares are owned by institutional investors?
    203.3M HALO shares are owned by institutional investors
  • How many HALO shares are owned by insiders?
    11.5M HALO shares are owned by insiders